| 发明名称 | Integrin α-Vβ8 neutralizing antibody | ||
| 摘要 | The present invention relates to αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter. | ||
| 申请公布号 | US9290572(B2) | 申请公布日期 | 2016.03.22 |
| 申请号 | US201113580105 | 申请日期 | 2011.02.18 |
| 申请人 | The Regents of the University of California | 发明人 | Nishimura Stephen;Lou Jianlong;Baron Jody Lynn;Marks James D. |
| 分类号 | C07K16/00;C07K14/705;C07H21/00;C12P21/06;C12P19/34;C07K16/28;A61K39/00 | 主分类号 | C07K16/00 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. An isolated antibody that specifically binds αvβ8, wherein the antibody has a heavy chain variable region which comprises a CDR1 sequence of SEQ ID NO: 5, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 7, and a light chain variable region which comprises a CDR1 sequence of SEQ ID NO: 8, a CDR2 sequence of SEQ ID NO: 9, wherein Xaa in SEQ ID NO:9 is tyrosine, and a CDR3 sequence of SEQ ID NO: 10. | ||
| 地址 | Oakland CA US | ||